The new vaccines: Building viruses that elicit antitumor immunity

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 658-663

  Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; EXPRESSION VECTOR; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; REVIEW; TUMOR IMMUNITY;

EID: 0030271764     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80082-3     Document Type: Article

References (54)

1. Coley WH. Further observations upon the treatment of malignant tumors with the toxins of erysipelar and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hosp. 7:1986;157-167.
2. Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today. 16:1995;334-336.
3. Van Pel A, Van der Bruggen P, Coulie PG, Brichard VG, Lethe B, Van den Eynde B, Uyttenhove C, Renauld JC, Boon T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev. 145:1995;229-250.
4. Pardoll DM. Tumour antigens. A new look for the 1990s [news; comment]. Nature. 369:1994;357.
5. d molecule.
6. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:1994;4155-4161.
7. of special interest Restifo NP, Bacik I, Irvine KR, Yewdell JW, McCabe BJ, Anderson RW, Eisenlohr LC, Rosenberg SA, Bennink JR. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol. 154:1995;4414-4422 We describe the in vivo functions of recombinant immunogens that make key elements of the antigen processing machinery superfluous. Using constructs designed by Jack Bennink, Jon Yewdell and their colleagues, we found that vaccinia viruses containing minigenes encoding peptide antigens that are directed to the ER can, in some cases, greatly improve their abilities to elicit cytotoxic T lymphocyte responses. The practical consequences of this work in the design of recombinant anticancer vaccines is described in more detail elsewhere (see [6,8,36]).
8. Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol. 154:1995;4651-4657.
9. Ciernik IF, Berzofsky J, Carbone DP. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma. 14:1995;139-142.
10. + T cells bind to peptides in a specialized endosomal compartment. To direct antigens to this compartment and increase the efficiency of MHC class II loading, investigators employed the sorting signal of LAMP-1. When expressed by a reconbinant vaccinia virus, intracellular antigen targeting augmented helper as well as cytotoxic antigen-specific immune responses.
11. + T lymphocytes in the function of recombinant vaccines.
12. of special interest Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol. 154:1995;5282-5292 Inoculation of mice bearing β-gal-expressing tumors with a recombinant vaccinia virus encoding β-gal was marginally therapeutic, but addition of exogenous IL-2 to the treatment regimen greatly improved efficacy. Similar augmentation was seen upon insertion of the cDNA for IL-2 into the viral genome. This study served as a prototype for the building of viruses capable of mediating the expression of antigen together with one or more immunomodulatory molecules.
13. of special interest Meko JB, Yim JH, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 55:1995;4765-4770.
14. + T lymphocytes play a critical role in the antitumor immune response. These cells are efficiently activated by specialized APCs called dendritic cells. This commentary details the prospects for the use of dendritic cells ad adjuvants for anticancer vaccines.
15. of outstanding interest Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 183:1996;283-287 The authors study immune reactivities using a model system consisting of the B16 tumor cell line, designated MO5, that has been transfected with the gene encoding chicken OVA. Dendritic cells pulsed with OVA peptide are shown to induce protective immunity to lethal challenge by MO5. Mice that have rejected the transfected tumor are then protected from challenge with the parent tumor, B16.
16. + T cells are required for these effects.
17. of special interest Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 183:1996;317-322 Using β-gal as a model TAA, fresh bone marrow derived dendritic cells loaded with the model antigen primed cytotoxic T lymphocyte responses and elicited protective immunity to a lacZ (gene encoding β-gal) transfected tumor cell line.
18. of special interest Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 2:1996;52-58.
19. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med. 182:1995;255-260.
20. + T lymphocytes.
21. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 7:1995;682-686.
22. of special interest Leach DR, Krummel MF, Sllison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1996;1734-1736 A great deal of attention has been focused on costimulatory signals that activate immune responses. Negative signals could thwart the generation of antitumor responses, however. One such signal may be provided by CTLA-4, a counter-receptor in the B7 family. In this report, CTLA-4 blockade resulted in the immune rejection of established tumors (see also [21]).
23. of special interest Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192 Another important negative regulatory signal originates from the interation of Fas (CD95) and Fas ligand. Using the eye as a site to study the phenomenon of immune `privilege' (i.e. a site where destructive inflammation does not occur) these investigators show that ocular invasion with inflammatory cells that do not undergo apoptosis occurs in mice lacking Fas ligand. They furthermore show that Fas-positive but not Fas-negative tumor cells undergo apoptosis when placed within isolated anterior segments of the eyes of normal but not Fas ligand negative mice.
24. Zheng L, Fisher G, Miller Re, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 377:1995;348-351.
25. Pardoll D. Releasing the brakes on antitumor immune response. Science. 271:1996;1691.
26. Chamberlain RS, Carroll MW, Bronte V, Warren S, Yang YC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Costimulation enhances the active immunotherapy effect of recombinant anti-cancer vaccines. Cancer Res. 56:1996;2832-2836.
27. Rao JB, Chamberian RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol. 156:1996;3357-3365.
28. Herlyn D, Somasundaram R, Li W, Jacob L. Animal models of human-derived cancer vaccines. Cell Biophys. 27:1995;15-30.
29. Restifo NP, Marincola FM, Kawakami Y, aiTaubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 88:1996;100-108.
30. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 16:1995;487-494.
31. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Benink JR. Identification of human cancers deficient in antigen processing. J Exp Med. 177:1993;265-272.
32. of special interest Rosenberg SA, White DE. Vitiligo in patients with melanoma normal tissue antigens as targets for cancer immunotherapy. J Immunother. 19:1996;81-84 Most of the melanoma antigens recognized by T lymphocytes are normal differentiation antigens that are also expressed by melanocytes. One obvious complication of this `self' recognition is vitiligo, as patchy loss of pigmentation in the skin and hair. This study details patients treated with IL-2. The development of vitiligo in this setting augurs a clinical response, although not all patients who responded developed vitiligo. Control kidney cancer patients receiving the same treatment did not develop vitiligo, regardless of their response.
33. of outstanding interest Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 182:1995;1609-1614 Using monoclonal antibodies against gp75 (also called tyrosinase-related protein 1, the product of the brown locus) these workers successfully treated animals bearing melanoma tumor cells. Most surprisingly, they also observed coat color changes (black to white) in the regenerating hairs of C57BL/6 mice. This system provides an excellent experimental animal model for autoimmune vitiligo and for the immunotherapy of melanoma.
34. of special interest Houghton AN, tiOn course for a cancer vaccine. Lancet. 345:1995;1384-1385 This article concisely summarizes the promises and pitfalls for the use of recombinant and synthetic anticancer vaccines in the clinic. In particular, issues concerning autoimmune reactivities are criticized as they relate to the elicitation of antitumor immune responses.
35. Wang M, Chen PW, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor antigen. J Immunother. 18:1995;139-146.
36. McCabe BJ, Irvine KR, Nishimura MI, Yang JC, Spiess PJ, Shulman EP, Rosenberg SA, Restifo NP. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. 55:1995;1741-1747.
37. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor Ja. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55:1995;3598-3603.
38. Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol. 23:1996;118-134.
39. + response against endogenously produced epitopes of K-Ras epitopes in a mouse model.
40. of special interest Brichard VG, Warnier G, Van Pel A, Morlighem G, Lucas S, Boon T. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur J Immunol. 25:1995;664-671 The murine mastocytoma P815 is a very useful model in the development of new immunotherapeutic strategies employing recombinant vaccines. Cytotoxic T lymphocyte responses against five different epitopes that are expressed by P815 cells are compared.
41. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides [see comments]. Nat Med. 1:1995;1179-1183.
42. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature. 369:1994;67-71.
43. of outstanding interest Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Psternack G, Cotter R, Hunt D, et al. The immunodominant MHC class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA. 1996; These investigators employed high performance liquid chromatography (HPLC) and microcapillary HPLC/triple quadruple mass spectrometry to identify a peptide expressed by the experimental murine tumor CT26, which is recognized by antitumor cytotoxic T lymphocytes. This apparently immunodominant epitope is a nonmutated nonamer derived from the gp70 envelope protein of an endogenous murine leukemia provirus. This new model promises to be extremely useful in the development of new anticancer vaccines.
44. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 2:1995;45-59.
45. Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk W, Carroll MW, Roberts B, Restifo NP, Rosenberg SA. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1996;. in press.
46. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA. A recombinant vaccinia virus expressing human prostatespecific antigen (PSA): safety and immunogenicity in a nonhuman primate. Int J Cancer. 63:1995;231-237.
47. Carroll Mw, Overwijk W, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as a recombinant vector for cancer immunotherapy. Vaccine. 1996;. in press.
48. Plotkin SA, Cadoz M, Meignier B, Meric C, Leroy O, Excler JL, Tartaglia J, Paoletti E, gonczol E, Chappuis G. The savety and use of canarypox vectored vaccines. Dev Biol Stand. 84:1995;165-170.
49. Chen Pw, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol. 156:1996;224-231.
50. Randrianarison-Jewtoukoff V, Perricaudet M. Recombinant adenoviruses as vaccines. Biologicals. 23:1995;145-157.
51. Ansardi DC, Moldoveanu Z, Porter DC, Walker DE, conry RM, LoBuglio AF, McPherson S, Morrow CD. Characterization of poliovirus replicons encoding carcinoembryonic antigen. Cancer Res. 54:1994;6359-6364.
52. Johanning FW, Conry RM, LoBuglio AF, Wright M, Sumerel LA, Pike MJ, Curiel DT. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res. 23:1995;1495-1501.
53. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, Curiel DT. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 2:1995;59-65.
54. of special interest Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol. 156:1996;238-245 Because of the ease of preparing plasmid DNA for safe use in humans, DNA immunization is an attractive alternative to live recombinant viruses for use in patients with infectious diseases and cancers. Using plasmid DNA encoding a model TAA coated onto gold particles, then propelled into epidermal cells using a `gene gun', small tumors could be successfully treated, but only when used in combination with cytokines involved in the growth and differentiation of T lymphocytes. IL-12 was found to have the most profound effect.